Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BGC101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Marius Nacht
Deal Size : $16.0 million
Deal Type : Financing
Details : Financing will support BioGenCell's innovative, accessible and painless medical platform focuses on BGC101 and pipeline. The product BGC101, treats severe limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers.
Brand Name : BGC101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : BGC101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Marius Nacht
Deal Size : $16.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?